Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

KK2223

Phase 1Small molecule

KKyowa Kirin, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

T-Cell NHL (PTCL or CTCL)Recruiting

T-Cell NHL (PTCL or CTCL)Phase 1

Recruiting

Timeline

Expected Milestones

Q3 2030

Phase 1Recruiting

T-Cell NHL (PTCL or CTCL)

NCT07192471

Clinical

Trials by Indication[1]

T-cell NHL (PTCL or CTCL)1 trial

A Phase 1, Multicenter, Open-label, Non-randomized, Dose-escalation and Backfill Study of KK2223 in Participants With Relapsed or Refractory T-cell Non Hodgkin Lymphoma

Recruiting·KKyowa Kirin, Inc.·Phase 1·NCT07192471·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KK2223. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KK2223 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KK2223. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kyowa Kirin, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: KKyowa Kirin, Inc.

Related News